期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 25, 期 7, 页码 1635-1642出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2015.01.028
关键词
Factor XIa; Anticoagulant; Thrombosis; Bioavailability; Serine protease
资金
- U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]
- companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute
Compound 2 was previously identified as a potent inhibitor of factor XIa lacking oral bioavailability. A structure-based approach was used to design analogs of 2 with novel P1 moieties with good selectivity profiles and oral bioavailability. Further optimization of the P1 group led to the identification of a 4-chlorophenyltetrazole P1 analog, which when combined with further modifications to the linker and P2' group provided compound 32 with FXIa K-i = 6.7 nM and modest oral exposure in dogs. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据